Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y.
Mitsuhashi A, et al.
Nat Commun. 2015 Dec 4;6:8792. doi: 10.1038/ncomms9792.
Nat Commun. 2015.
PMID: 26635184
Free PMC article.